Cantargia patent granted in Australia

Cantargia AB (”Cantargia”) has obtained a granted patent in Australia concerning IL1RAP as a target molecule for antibody based therapy and diagnostic methods of leukemia.

Based on this grant, Cantargia´s method for treatment of leukemia has protection within Europe, South Africa and Australia. The corresponding application is currently under review by authorities in e.g. USA, Japan and China.

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60

About Us

Cantargia AB (publ), 556791-6019, is a biotech company which is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at


Documents & Links